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Mesenchymal stem cells (MSCs) can be infected with prions and have been proposed as in vitro
cell-based models for prion replication. In addition, autologous MSCs are of interest for cell
therapy in neurodegenerative diseases. To the best of our knowledge, the effect of prion diseases
on the characteristics of these cells has never been investigated. Here, we analysed the
properties of MSCs obtained from bone marrow (BM-MSCs) and peripheral blood (PB-MSCs) of
sheep naturally infected with scrapie — a large mammal model for the study of prion diseases.
After three passages of expansion, MSCs derived from scrapie animals displayed similar
adipogenic, chondrogenic and osteogenic differentiation ability as cells from healthy controls,
although a subtle decrease in the proliferation potential was observed. Exceptionally,
mesenchymal markers such as CD29 were significantly upregulated at the transcript level
compared with controls. Scrapie MSCs were able to transdifferentiate into neuron-like cells, but
displayed lower levels of neurogenic markers at basal conditions, which could limit this potential.
The expression levels of cellular prion protein (PrPC) were highly variable between cultures, and
no significant differences were observed between control and scrapie-derived MSCs. However,
during neurogenic differentiation the expression of PrPC was upregulated in MSCs. This
characteristic could be useful for developing in vitro models for prion replication. Despite the
infectivity reported for MSCs obtained from scrapie-infected mice and Creutzfeldt–Jakob disease
patients, protein misfolding cyclic amplification did not detect PrPSc in BM- or PB-MSCs from
scrapie-infected sheep, which limits their use for in vivo diagnosis for scrapie.
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INTRODUCTION
Prion diseases or transmissible spongiform encephalopathies
(TSEs) are a group of fatal neurodegenerative diseases
characterized by the accumulation of pathological isoforms
(PrPSc) of the cellular prion protein (PrPC) in the brain,
but also in lymphoid tissue and to a lesser extent in other
tissues (Safar et al., 1993).
Stem cell-based therapies have emerged as possible strategies
to treat diseases of the central nervous system (Lindvall &
Kokaia, 2010). Mesenchymal stem cells (MSCs) display
certain characteristics that make them good candidates for
the treatment of neurodegenerative diseases. For example,
MSCs can transdifferentiate into neuron and glial cells
(Chen et al., 2001), although the functionality of differen-
tiated cells is controversial (Przyborski et al., 2008).
In addition, these cells release angiogenic, neurogenic, neu-
roprotective, synaptogenic and scarring inhibition factors,
which could exert a neuroprotective effect (Chen &
Chopp, 2006). Transplantation of human MSCs in mice
infected with prions does not arrest disease progression,
but increases survival times (Song et al., 2009), and brain
extracts from prion-infected mice promote chemotaxis of
MSCs in vitro. The chemokine receptors involved in the
migration of human MSCs to brain lesions have also been
identified (Song et al., 2011).3These authors contributed equally to this paper.
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In addition to their use as therapy, stem cells are being used
in prion research as possible in vitro models for prion
propagation. A wide variety of stem cells express PrPC,
including MSCs (Mohanty et al., 2012), and the function
of this protein has been linked to stem cell biology (Lee
& Baskakov, 2013; Zhang et al., 2006). In recent years,
three bioassays have used murine cells with mesenchymal
characteristics to multiply different prion strains previously
adapted in mice (Akimov et al., 2008, 2009; Cervenakova
et al., 2011). The development of such in vitro models
in species naturally susceptible to the disease would
avoid the species barrier. Our group presented the first
in vitro characterization of peripheral blood-derived
ovine MSCs (PB-MSCs) and demonstrated that these
cells express PrPC, at least at the transcript level (Lyahyai
et al., 2012).
Finally, the determination of infectivity in MSCs obtained
from individuals affected with prion diseases has been
proposed for in vivo diagnosis for TSEs. Murine models
experimentally infected with prions accumulate PrPSc in
bone marrow-derived MSCs (BM-MSCs) and this infection
could precede prion accumulation in brain (Takakura et al.,
2008). MSCs can also be found in peripheral blood, and
the presence of PrPSc has been demonstrated in several
fractions of human and ovine blood (Andre´oletti et al.,
2012), in plasma and cells from different haematopoietic
lineages. Whether circulating MSCs are infective or not is
still unknown.
In addition to the therapeutic potential for their use in
autologous transplants, the effect of prion disease in the
characteristics of MSCs has never been investigated. Here,
to the best of our knowledge, we present the firstwork focused
on the characterization of BM- and PB-MSCs obtained from
sheep naturally infected with scrapie – a prion disease that
affects sheep and goats (Detwiler, 1992). Changes in PrPC
expression either related to the disease or induced by the
neurogenic differentiation process have been evaluated in
the present work, as well as the possible presence of PrPSc in
both types of cells.
RESULTS
Mesenchymal characteristics of scrapie-derived
MSCs
The mesenchymal characteristics concerning proliferation,
differentiation potential and expression of mesenchymal
cell surface markers were evaluated in BM- and PB-MSCs
of healthy (H) and scrapie-infected (Sc) sheep in a clinical
phase of the disease.
Isolation of MSCs and their proliferation potential
Plastic-adherent fibroblast-like cells were observed in all
donor samples obtained from bone marrow aspirates and
peripheral blood within the first days of culture. A great
variability was observed in the number of adherent cells
obtained at the end of passage 0, and no statistically signifi-
cant differences were observed between cultures derived
from healthy and scrapie-infected individuals (Table 1).
The proliferation ability of PB- and BM-MSCs obtained from
healthy and scrapie-infected sheep was analysed during the
first three passages. Mean culture time to complete a passage
was 6.2 days for PB-MSCs and 7.8 days for BM-MSCs. Cell
doubling (CD) and doubling time (DT) results are shown
in Table 1. CD was significantly lower in Sc-PB-MSCs than
in H-PB-MSCs at passages 1 and 3. In the same way, Sc-
BM-MSCs displayed a decrease of CD, and this change was
significant at passages 2 and 3 compared with H-BM-MSCs.
In spite of these changes, DT results did not show statistically
significant differences between healthy and scrapie MSCs.
Expression of cell surface markers
Quantitative real-time (qRT)-PCR was used to analyse
seven mesenchymal and two haematopoietic surface mark-
ers; results are shown in Fig. 1. The amplification of the
MSC-specific surface markers CD29, CD36, CD73, CD90
and CD166 was successful in both PB-MSCs and BM-MSCs
obtained from healthy or scrapie-infected sheep. Differences
Table 1. Proliferation of MSCs derived from healthy and scrapie-infected sheep
Number of adherent cells at the end of passage 0 and CD/DT for the three first passages are shown (mean¡SD).
Passage Parameter BM-MSCs PB-MSCs
Healthy Scrapie Healthy Scrapie
0 Adherent cells (6103) 379¡231 385¡363 596¡427 630¡369
1 CD 3.06¡0.57 2.98¡0.75 2.92¡0.31 1.70¡1.12*
DT (days) 2.18¡0.60 2.42¡1.45 1.88¡0.56 10.15¡14.64
2 CD 2.9¡0.35 1.9¡0.84* 2.14¡0.79 2.06¡0.63
DT (days) 2.42¡0.35 3.57¡1.71 4.17¡3.56 2.79¡0.59
3 CD 2.61¡0.18 1.97¡0.50* 2.51¡0.35 1.84¡0.38*
DT (days) 3.32¡0.68 2.55¡1.14 2.63¡0.87 2.99¡0.76
*P,0.05 (Student’s t-test).
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between tissue sources were observed for the expression
of the CD105 MSC marker. This marker was not detectable
in BM-MSC cultures, but it was properly amplified in PB-
MSCs (Fig. 1). The expression of haematopoietic markers
was also analysed; whereas CD45 was absent in all PB-MSCs
and only one H-BM-MSC culture showed mRNA expression
for this marker, the expression of CD34 was variable for
the different cultures (four of five H-BM-MSCs, one of
four Sc-BM-MSCs, two of five H-PB-MSCs and two of five
Sc-BM-MSCs; data not shown). When the expression of
these markers was compared between healthy and scrapie-
infected MSCs, only CD29 was significantly upregulated by
Sc-BM-MSCs and the remaining markers showed no differ-
ences related to the disease condition.
Cross-reactivity of seven anti-human MSCmarker antibodies
was tested in two H-BM-MSC, two Sc-BM-MSC and one
Sc-PB-MSC cultures. Ovine MSCs displayed large size and
complexity, and a lack of immunoreactivity was observed for
the isotype controls for each mouse mAb (Fig. 2). Ovine
MSCs derived from the two sources were robustly positive
for the typicalMSCmarker CD29, showingw97 %of positive
cells. On the contrary, these cultures displayed low and
variable percentages of CD90 and CD105 immunoreactive
cells (Fig. 2),whichmayhave resulted fromunspecific antibody
reactions. We could not expand the putative markers set with
other antibodies as the cultures were negative for CD14,
CD19 and CD73 (data not shown). Immunoreactivity against
the haematopoieticmarker CD45was not detected in any case.
The immunophenotype for CD29 was evaluated in nine
PB-MSC (four scrapie-infected and four healthy) and in
seven BM-MSC cultures (four scrapie-infected and three
healthy). In accordance with gene expression, the percent-
age of CD29+ cells and the fluorescence intensity were
higher in PB-MSCs than in BM-MSCs (Pv0.05), but sig-
nificant differences were not observed between cultures
derived from scrapie-infected and healthy sheep (Fig. 2).
Adipogenic, osteogenic and chondrogenic
differentiation
The adipogenic differentiation potential was analysed by
specific Oil Red O dying and microscopic observation.
Translucent intracellular droplets of variable size and
number were observed across their differentiation process;
Oil Red O staining confirmed their lipid nature (Fig. 3).
In addition, the expression of GPAM (mitochondrial gly-
cerol-3-phosphate acyltransferase), PPARG (peroxisome
proliferator-activated receptor c) and SCD (stearoyl-CoA
desaturase) was analysed by qRT-PCR at the end of the
differentiation process (day 14 of culture for BM-MSCs
and day 21 of culture for PB-MSCs). Although high vari-
ability was observed within groups of cultures, a statistically
significant difference between differentiated and undiffer-
entiated cells was observed for the upregulation of the
adipogenic marker PPARG in Sc-BM-MSCs (Pv0.05), and
GPAM in differentiated H-PB-MSCs (Pv0.01) and Sc-PB-
MSCs (Pv0.05). PB-MSCs took longer to differentiate
into adipocytes (21 versus 14 days for BM-MSCs).
The chondrogenic differentiation potential of MSCs was
evaluated by Alcian Blue G dying, which stains glycosamino-
glycans generated during chondrogenesis. The differen-
tiation process was arrested when solid formations were
observed on the plate (28 days for BM-MSCs and 21 days
for PB-MSCs). These formations were stained in blue, indi-
cating a correct differentiation process, although the
staining was more intense in BM-MSCs than in PB-MSCs
(Fig. 3). In addition, chondrogenic markers BGN (biglycan),
COL2A1 (collagen, type II, a1) and LUM (lumican) were ana-
lysed by qRT-PCR assay. In cultures obtained from healthy
sheep, BGN was significantly downregulated in differentiated
BM-MSCs (Pv0.05) and upregulated in differentiated PB-
MSCs (Pv0.05) (Fig. 3). These differences could reflect two
different moments in the kinetics of the chondrogenic pro-
cess. The comparison between scrapie-infected and healthy
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Fig. 1. Expression of cell surface markers. Gene expression of mesenchymal and haematopoietic cell surface markers quantified
by qRT-PCR in (a) BM-MSCs and (b) PB-MSCs. Relative mRNA expression levels are expressed as mean¡SEM. Significant
differences between healthy and scrapie-derived cultures were calculated with Student’s t-test (*P,0.05).
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cultures only revealed a significant downregulation of BGN in
Sc-BM-MSCs at basal conditions.
The osteogenic differentiation ability of MSCs was confirmed
using Alizarin Red S staining to detect calcium deposits.
Red-dyed nodular aggregations were observed, demonstrat-
ing the mineralization process (Fig. 3). Quantification of
osteogenic marker expression by qRT-PCR revealed a signifi-
cant downregulation of COL1A1 (collagen type I, a1) in dif-
ferentiated Sc-BM-MSCs (Pv0.05). The variability observed
between groups did not allow the detection of significant
differences between scrapie-infected and control cultures.
Transdifferentiation into neuronal-like cells
The potential of MSCs to transdifferentiate into neuronal-like
cells was evaluated in vitro in cells obtained from bone
marrow and peripheral blood from healthy and scrapie-
infected sheep.Direct observation bymicroscopy showedmor-
phological changes after 3 days of culture under neurogenic
conditions. MSCs changed their fibroblast-like appearance
into sharply defined shapes and retracted toward the nucleus,
with some neurite-like processes (Fig. 4). Neurogenic differen-
tiation was also evaluated using qRT-PCR analysis of the
neurogenic markersNEFM (neurofilament, medium polypep-
tide),NES (nestin) andTUBB3 (tubulin,b3 class III). Although
morphology was clearly altered in the differentiated cultures,
the expression of neurogenic markers in differentiated cells
did not display statistically significant changes at day 3; only
NES and TUBB3 were significantly downregulated in differen-
tiated Sc-PB-BMCs (Pv0.05) and H-BM-MSCs (Pv0.01),
respectively (Fig. 4). Downregulation of these neurogenic
markers was also observed in MSC cultures derived from
scrapie-infected sheep at basal levels: NES in Sc-BM-MSCs
(Pv0.05) and TUBB3 in Sc-PB-MSCs (Pv0.05) (Fig. 4).
PrPC gene and protein expression
The expressionof the prion proteinwas confirmed at the tran-
script level by qRT-PCR in the different cell types (Fig. 5).
The expression was quantified at basal conditions and after
3 days of culture under neurogenic conditions. Changes in
PRNP expression related to the disease were not observed.
A dot-blotting assay confirmed the expression of PrPC by
ovine MSCs, displaying high variability between cultures.
This assay validated the lack of differences in PrPC expression
between healthy and scrapie-infected cultures at basal con-
ditions (Fig. 5).
The expression of the PRNP gene was not significantly
modified after neurogenic differentiation either in BM- or
PB-MSCs, although a trend to increase its expression was
observed mainly in differentiated BM-MSCs from both
control and scrapie-infected sheep (Fig. 5). Dot-blotting
was performed at day 9 of neurogenic differentiation in a
reduced number of cultures. The expression of PrPC was
analysed in four BM-MSC cultures (two from healthy
sheep and two from scrapie-infected sheep). Three of these
cultures appeared to increase the expression of PrPC under
neurogenic conditions; however, the PrPC signal decreased
in one of the scrapie-infected cultures under neurogenic
differentiation (Fig. 5). A similar assay was performed in
six PB-MSC cultures (three from healthy sheep and three
from scrapie-infected sheep). In this case, differentiated cul-
tures obtained from scrapie-infected sheep displayed a sig-
nificant PrPC upregulation (Pv0.05) compared with their
controls under growth conditions (Fig. 5).
Determination of PrPSc in MSCs
A blind protein misfolding cyclic amplification (PMCA)
analysis was developed to detect PrPSc in BM- and PB-
MSC cultures obtained from healthy and scrapie-infected
sheep at passage 3. None of the cultures displayed a seed
able to amplify PrPSc after five rounds of PMCA. Under the
same conditions, this technique amplified a 10212 dilution
of a scrapie ARQ 10 % brain homogenate. To test if PrPSc
was lost during MSC expansion, bone marrow mononuclear
cells and passage 1 BM-MSCs derived from two scrapie-
infected sheep were also analysed by PMCA. None of them
displayed detectable replication of PrPSc.
DISCUSSION
MSCs have been proposed as good candidates for cell
therapy in neurodegenerative diseases. MSCs can be isolated
from different tissues, including the accessible bone marrow
or even peripheral blood. The key benefit of adult stem cells
such as MSCs is their potential use in autologous therapies,
avoiding the ethical concerns and risks of embryonic stem
cells (Dantuma et al., 2010). During recent years, the poten-
tial of MSCs for the treatment of neurodegenerative path-
ologies such as Alzheimer’s disease, Parkinson’s disease or
amyotrophic lateral sclerosis (ALS) has been investigated
(for review, see Tanna & Sachan, 2014).
Prion diseases are fatal neurodegenerative pathologies that
affect humans and animals. As there is no effective treatment
for this group of diseases, they are candidates for stem cell
therapy. Human MSCs inoculated in mice infected with
scrapie migrate to prion lesions in the brain, differentiate
Fig. 2. Representative flow cytometry plots showing (a) ovine MSC morphology, (b) isotype controls of mouse mAbs for FITC
and phycoerythrin (PE), (c) SYTOX Blue staining for dead cells, and results for the markers CD29, CD90 and CD105 in (d–
f) BM-MSCs and (g–i) PB-MSCs. The bar charts below the plots show (j) percentages of CD29 immunoreactive cells in
scrapie-infected (Sc) and healthy (H) BM- and PB-MSCs, and (k) percentages of CD29 immunoreactive cells and (l) mean
fluorescence intensity (MFI) in BM- and PB-MSCs. Data are presented as mean¡SEM. Significant differences between bone
marrow and peripheral blood were calculated with Student’s t-test (*P,0.05).
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Fig. 4. Neurogenic differentiation of BM- and PB-MSCs of healthy and scrapie-infected sheep. Phase-contrast micrographs
of H-BM-MSCs under (a) basal and (b) neurogenic conditions, (c) basal Sc-BM-MSCs, (d) differentiated Sc-BM-MSCs,
(f) basal H-PB-MSCs, (g) differentiated H-PB-MSCs, (h) basal Sc-PB-MSCs, and (i) differentiated Sc-PB-MSCs. Bar charts
show the relative expression levels of neurogenic markers for (e) BM-MSCs and (j) PB-MSCs quantified by qRT-PCR.
Significant differences were calculated with Student’s t-test (*P,0.05). Ctrl, Control (basal); Neu, neurogenic.
Fig. 3. Adipogenic, chondrogenic and osteogenic differentiation of BM- and PB-MSCs of healthy and scrapie-infected
sheep. Oil Red O staining of (a) H-BM-MSCs, (b) Sc-BM-MSCs, (d) H-PB-MSCs and (e) Sc-PB-MSCs cultured under adi-
pogenic differentiation conditions. Alcian Blue staining of (g) H-BM-MSCs, (h) Sc-BM-MSCs, (j) H-PB-MSCs and (k) Sc-
PB-MSCs cultured in chondrogenic medium. Alizarin Red staining of (m) H-BM-MSCs, (n) Sc-BM-MSCs, (p) H-PB-MSCs
and (q) Sc-PB-MSCs cultured in osteogenic differentiation medium. Quantification by qRT-PCR of (c, f) adipogenic, (i, l)
chondrogenic and (o, r) osteogenic markers. Significant differences between expression levels were calculated with Student’s
t-test (*P,0.05; **P,0.01). Dif, Differentiation; Ctrl, control.
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into cells with neuronal and glial characteristics, and increase
the lifespan of scrapie-infected mice (Song et al., 2009).
Before their use in autologous therapy, the effect of the dis-
ease on the characteristics of MSCs should be investigated.
To the best of our knowledge, this is the first study analysing
the mesenchymal characteristics of BM- and PB-MSCs in a
prion disease model. Scrapie in sheep can be regarded as a
good model for the human prion diseases and could be
used for testing new therapies, such as those based on regen-
erative medicine.
Brains from prion-infected mice segregate chemoattractive
factors that attract MSCs to brain lesions associated with
prion replication (Song et al., 2009, 2011). Our results
suggest that MSCs are not mobilized in the natural disease
because we obtained adherent fibroblast-like cells from
peripheral blood and bone marrow of all the animals ana-
lysed, and no differences related to the disease.
A lower growth potential has been suggested in MSCs
obtained from patients with other neurodegenerative dis-
eases, such as ALS (Bossolasco et al., 2010; Ferrero et al.,
2008) or multiple sclerosis (Mallam et al., 2010); however,
this decrease has always been not significant and in other dis-
eases like Parkinson’s,MSCs frompatients did not differ from
control cultures (Zhang et al., 2008). In our study, PB- and
BM-MSCs from scrapie-infected sheep displayed a signifi-
cantly lower CD parameter during the three first passages,
which could indicate a lower proliferation potential, although
this reduction was not confirmed with the DT parameter.
All cells from both origins and disease status expressed the
MSC surface markers CD29, CD73 and CD90 at the transcript
level. The expression of haematopoietic marker CD45mRNAs
in one of the H-BM-MSC cultures could be due to contami-
nation with haematopoietic cells, although its expression has
been described in MSCs from haematologic disease patients
and, under certain culture conditions, this marker can be
expressed by MSCs (Yeh et al., 2006). Similarly, although
CD34 is considered an haematopoietic progenitor marker,
there is evidence of CD34 expression by MSCs derived from
different tissues, including bone marrow or peripheral blood
(Lin et al., 2012; Lyahyai et al., 2012; Ranera et al., 2011).
As a consequence, BM- and PB-MSCs from healthy and
scrapie-infected sheep displayed a gene expression profile com-
patible with the mesenchymal origin of these cells.
The expression of these markers was evaluated at the protein
level by flow cytometry. Due to the lack of specific antibodies
for ovine epitopes, several studies have tested the cross-
reactivity between anti-human antibodies and ovine cell
surface proteins (Boxall & Jones, 2012; McCarty et al.,
2009; Mrugala et al., 2008). We used a panel of seven
anti-human antibodies, some of which have shown
immunoreactivity against epitopes from other mammalian
species, such as horses (Ranera et al., 2011). This analysis
confirmed the high expression of CD29 by ovine MSCs;
however, as in other works, most of the anti-human anti-
bodies did not display cross-reactivity against ovine cell sur-
face markers (Boxall & Jones, 2012).
The only difference observed between healthy and scrapie-
infected cultures was a slight increase of CD29 transcripts
in Sc-BM-MSCs. This difference was not confirmed at the
protein level due to the high variability observed along the
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study. PrPC contributes to neuronal polarization through
spatially organizing b1-integrins (CD29) at the plasma
membrane but does not modify total b1-integrin expression
levels (Loubet et al., 2012). Further investigations are
necessary to confirm if the variability observed in CD29
protein levels can affect the ability of these cells to
differentiate into neuronal-like cells.
MSCs from ALS and Parkinson’s disease patients display
abilities to differentiate into the three mesodermal lineages
(Bossolasco et al., 2010; Zhang et al., 2008). In our study,
cells were maintained under differentiation conditions until
they showed morphology and staining compatible with
adipogenic, chondrogenic or osteogenic differentiation.
In general, high variability was observed within groups of
donors. The heterogeneity in differentiation potential between
MSC donors has been described in many species (Lei et al.,
2013; Lyahyai et al., 2012; Ranera et al., 2012; Siegel et al.,
2013). This variability makes the comparison of MSCs from
scrapie and healthy animals difficult. Nevertheless, the few
significant changes related to the disease represented a down-
regulation of differentiation markers (BGN and COL1A1) in
cells obtained from affected individuals; this fact could reflect
a slight loss of differentiation potential.
Cultures derived from scrapie-infected sheep displayed a
morphology compatible with neurogenic differentiation,
and no clear differences were observed between scrapie-
infected and healthy cultures during the differentiation
process. Undifferentiated human MSCs express nestin
mRNA (Montzka et al., 2009) and the expression of the
nestin gene increases progressively with the number of pas-
sages in rat MSCs (Wislet-Gendebien et al., 2003), which
has been suggested to be an important stage in the ability to
differentiate into neuronal cells. Donor heterogeneity in the
expression levels of neurogenic markers has been described
in humans (Montzka et al., 2009). Similarly, ovine MSC
cultures analysed in our study displayed great variability in
the basal levels of neurogenic markers. However, in addition
to this variability, we found a statistically significant reduction
of NES and TUBB3 in scrapie-derived BM- and PB-MSCs,
respectively, that could limit their therapeutic potential
when used as autologous therapy.
BM-MSCs express PrPC and its expressiondecreaseswith pas-
sage number (Mohanty et al., 2012), aswell as their capacity to
proliferate (Wagner et al., 2009). This characteristic has been
used to develop in vitromodels for prionmultiplication based
on the culture and infection of murine MSCs (Akimov et al.,
2008, 2009; Cervenakova et al., 2011). We reported the
expression of PrPC in ovine PB-MSCs at the transcript level
(Lyahyai et al., 2012) and proposed ovine MSCs as good can-
didates to develop in vitromodels for prionpropagation in the
natural host (Mediano et al., 2015). In this work, we have con-
firmed the expression of the PrPC protein in both, BM- and
PB-MSCs. The disease appeared not tomodify the expression
of PrPC either at the transcript or at the protein level. Both
qRT-PCR and dot-blotting assays revealed a high variability
in PrPC expression between cultures. Heterogeneity in PrPSc
susceptibility has been reported for subclones of tumour cell
lines (Bosque & Prusiner, 2000; Mahal et al., 2007); however,
the susceptibility to prion infection was not correlated with
PrPC levels (Prusiner, 1991).
Neuro2A cells treated with retinoic acid, a compound used
for neuronal differentiation, overexpressed PrPC and were
more susceptible to prion infection (Bate et al., 2004). Pre-
viously (Lyahyai et al., 2012), we observed an upregulation
of PRNP transcripts during the neurogenic differentiation
process of ovine PB-MSCs. Although showing high vari-
ation, most MSC cultures also increased the expression of
PrPC during neurogenic differentiation that could help in
their further use for in vitro infection.
BM-MSCs from mice infected with prions and from
Creutzfeldt–Jakob disease (CJD) patients show infectivity
(Takakura et al., 2008), although there is a certain controversy
about the infectivity of bone marrow in human patients
(Brown et al., 1994). The infectivity of blood and blood cells
has been reported in scrapie-infected sheep (Halliez et al.,
2014; Lacroux et al., 2012) and CJD patients (Douet et al.,
2014). Our PMCA analysis did not detect the presence of
PrPSc either in PB- or BM-MSCs derived from sick animals
at passage 3. The infectivity does not seem to be lost during
their proliferation in culture because bone marrow mono-
nuclear cells and MSCs at passage 1 did not present PMCA-
replicable PrPSc. Although the infectivity of bone marrow
from scrapie-infected sheep has been reported (Hadlow
et al., 1982), our study does not corroborate the hypothesis
of bone marrow being the source of the prionaemia
described in sheep. Thus, infectivity of BM-MSCs cannot be
considered as a general feature for prion diseases and their
analysis cannot be used for in vivo diagnosis for scrapie.
To conclude, our study shows the characterization of MSCs
obtained from individuals affected with prion diseases.
BM- and PB-MSCs from scrapie-infected animals revealed
subtle differences in proliferation, an increase in CD29
expression at the transcript level, slight differences in the
expression of osteogenic and chondrogenic markers, and
downregulation of some neurogenic markers from basal
levels. Whether these slight modifications could have an
influence on their ability for autologous cell therapy needs
further investigation. Finally, neither PB- nor BM-MSCs
displayed PrPSc infectivity, and they cannot be used for
in vivo diagnosis of ovine scrapie. However, the increase of
PrPC during the neurogenic differentiation process could
help in developing new in vitro assays for the study of prion
disease biology based on the culture and infection of MSCs.
METHODS
Animals and sample collection. A total of 20 adult Rasa Aragonesa
female sheep were used in this study, 19 displayed the ARQ/ARQ
genotype for the PRNP gene and one sheep showed the AHQ/AHQ
genotype. Eleven of these sheep displayed clinical symptomatology of
scrapie and nine were considered as healthy, without any clinical signs
compatible with scrapie or with any other pathology. Animals that
displayed neurological symptoms were sacrificed and diagnosis was
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confirmed by determination of PrPSc in medulla oblongata samples as
described previously (Bolea et al., 2005).
Approximately 30 ml peripheral blood was collected from six scrapie-
infected and five healthy sheep by jugular venepuncture in tubes with
sodium heparin. After animal sedation (xylazine intravenously) and
local anaesthesia (lidocaine), bone marrow aspirates were harvested
from the humeral head of seven scrapie-infected and six healthy sheep
using a 13G Jameshdi needle and 10 ml syringes previously loaded
with 5000 IU sodium heparin. All procedures were carried out under
Project Licence PI06/12 approved by the Ethic Committee for Animal
Experiments from the University of Zaragoza. The care and use of
animals was performed accordingly with the Spanish Policy for
Animal Protection RD53/2013, which meets the European Union
Directive 2010/63 on the protection of animals used for experimental
and other scientific purposes.
Isolation and expansion of MSCs. MSC isolation from peripheral
blood (30 ml) and bone marrow aspirates (3–13 ml) was performed
as described previously (Lyahyai et al., 2012; Ranera et al., 2012). Both
protocols were based on the separation of the mononuclear fraction
after a density gradient centrifugation in Lymphoprep (Atom) for
20 min at 400 g. Mononuclear cells were plated at 106 cells cm22 in
six-well plates with basal medium, consisting of low-glucose Dulbecco’s
modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with
20 % FBS for PB-MSCs or 10 % FBS for BM-MSCs, and with 1 %
L-glutamine (Sigma-Aldrich) and 1 % streptomycin/penicillin (Sigma-
Aldrich). Cells were incubated at 37 uC and 5 % CO2, expanded until
passage 3, cryopreserved in FBS with 10 % DMSO and stored at
2150 uC for further characterization.
MSC proliferation. Adherent cells were counted at the end of pas-
sage 0 using a Neubauer chamber. Afterwards, MSCs were counted
through passages 0–3, and CD and DT parameters were calculated as
described previously (Lyahyai et al., 2012).
MSC characterization. In addition to plastic adherence under
standard culture conditions, the minimal criteria to define MSCs are
the expression of certain cell surface markers, and the ability to
differentiate into adipocytes, osteoblasts and chondroblasts in vitro
(Dominici et al., 2006).
The expression of mesenchymal (CD29, CD36, CD49, CD73, CD90,
CD166 and CD105) and haematopoietic (CD34 and CD45) cell sur-
face markers was evaluated at the transcript level by qRT-PCR. Total
RNA was extracted and converted to cDNA from 200 000 previously
frozen cells using a Cells-to-cDNA II kit (Ambion). Amplifications
were performed using primers and conditions described previously
(Lyahyai et al., 2012).
The expression of the surface markers at the protein level was analysed
by flow cytometry. First, a total of seven surface markers were
examined in five cultures (four BM-MSC and one PB-MSC): the
mesenchymal cell markers CD29 (integrin-1), CD44 (H-CAM), CD73
(ecto-59-nucleotidase), CD90 (Thy-1) and CD105 (endoglin), and the
haematopoietic markers CD34 and CD45 (LCA). The anti-human
mouse antibodies and the methodology have been described pre-
viously (Ranera et al., 2011). Before the FACS analysis (FACSAria; BD
Biosciences), viable and non-viable cells were discriminated using the
SYTOX Blue dead cell stain (Molecular Probes). Positive staining for
the CD markers was defined as the emission of a fluorescence signal
that exceeded levels obtained by w95 % of cells from the control
population stained with matched isotype antibodies. Dot-plots were
generated using FACSDiva 5.0.1 (BD Biosciences).
Afterwards, the expression of CD29 was evaluated by flow cytometry
in three H-BM-MSC, four Sc-BM-MSC, four H-PB-MSC and five
Sc-PB-MSC cultures by quantifying the fluorescence intensity and
percentage of positive cells.
Adipogenic, osteogenic and chondrogenic differentiation was devel-
oped in vitro following the previously described methodology (Ja¨ger
et al., 2006; Ranera et al., 2012) for both PB- and BM-MSCs. Cells
were maintained under differentiation conditions until most cultures
from the same group (BM- or PB-MSCs) displayed a morphology
compatible with differentiated cells. Adipogenic differentiation was
confirmed using a 0.3 % Oil Red O (Sigma-Aldrich) specific stain at
14 (BM-MSCs) or 21 days (PB-MSCs) of culture. Chondrogenic
differentiation was identified by Alcian Blue G dye (1 : 1 in methanol)
(Sigma-Aldrich) after 28 days of chondrogenic culture for BM-MSCs
and 21 days for PB-MSCs. Osteogenic differentiation was confirmed
by 2 % Alizarin Red S staining (Sigma-Aldrich) at 28 days of culture
in all cases. In addition, the expression of adipogenic (GPAM, PPARG
and SCD), chondrogenic (BGN, COL2A1 and LUM) and osteogenic
markers (BGLAP and COL1A1) was analysed by qRT-PCR on the
same day as staining. Primers used for GPAM qRT-PCR were (for-
ward: 59-CATACAAGCACCGAGGGT-39; reverse: 59-CAAACGGT-
GGTTGCATTGACTT-39), and primers and conditions for the
amplification of remaining markers and housekeeping genes were
those described previously (Lyahyai et al., 2010, 2012).
Transdifferentiation into neuron-like cells. The capacity of MSCs
to transdifferentiate into neuron-like cells was analysed by culturing
the cells with HyClone Neural Differentiation kit medium (Thermo
Scientific) as described previously (Lyahyai et al., 2012). The cultures
were studied by direct observation under a microscope at day 3
of neurogenic culture. Additionally, qRT-PCR was performed as
described previously (Lyahyai et al., 2012) to detect the expression of
neurogenic markers NEFM, NES and TUBB3 at day 3 of culture.
Expression levels in the differentiated cultures were compared with
cultures under basal conditions.
PrPC gene and protein expression. The expression of PrPC in PB-
and BM-MSCs was evaluated under basal and neurogenic conditions
by qRT-PCR and dot-blotting following standard procedures. Primers
and conditions for the amplification of PRNP and the housekeeping
genes were those described previously (Lyahyai et al., 2010). The
expression of this gene was evaluated under the same cell cultures as
neurogenic markers (see above).
For PrPC protein determination, 106 cells at basal conditions or after
9 days of neurogenic culture were homogenized in 500 ml PBS.
Samples of 10 mg total protein were deposited by dropping 7 ml on a
0.2 mm Immun-Blot PCDF (Bio-Rad) membrane, and PrPC was
determined using the mouse mAb anti-PrP IgG1 6H4 (Prionics) and
the alkaline phosphatase-conjugated goat anti-mouse IgG (Prionics)
as secondary antibody. CDP-Star substrate (Tropix) was used to
determine chemiluminescence in a Versa-Doc Imaging System (Bio-
Rad). Chemiluminescence signals were evaluated using ImageJ
1.4.3.67 (Psion Image) as described previously (Filali et al., 2013).
PMCA. In vitro prion replication experiments were performed as
described previously (Castilla et al., 2008). Briefly, 106 mesenchymal
cells from scrapie-infected (Sc-BM-MSCs n54, Sc-PB-MSCs n56) or
healthy (H-BM-MSCs n55, H-PB-MSCs n55) sheep were cen-
trifuged and pellets were resuspended in 120 ml Tg338 VRQ ovine
transgenic mice brain homogenate. The final volume was split in two
0.2 ml PCR tubes and samples were subjected to sonication (S-
700MPX; QSonica). The sonicator settings were 20 s at a power set-
ting of 70–80 % followed by 30 min of incubation for a total of 24 h
for each round, performed at 37–38 uC. Up to five serial rounds of
PMCA were performed and unseeded tubes were included as negative
controls. To test for PrPSc presence, all sonicated samples were
digested with 50–100 mg proteinase K ml21 for 1 h at 42 uC and
analysed by Western blotting. Blots were probed with anti-PrP mAb
9A2. The presence of PrPSc in bone marrow mononuclear cells
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obtained from two scrapie-infected sheep and MSCs from these two
sheep at passage 1 were also evaluated following the same procedure.
To ensure the proper sonicator operation and in order to discard
potential cross-contaminations, standard PMCA of Tg338 brain
homogenate seeded with ovine scrapie up to 10212 dilution was
performed at a later time.
Statistical methods. SPSS 15.0 was used for the statistical analysis.
Data obtained from qRT-PCR, flow cytometry and Western blotting
were analysed for normality with the Shapiro–Wilk test. Differences in
gene expression, reactivity levels and dot intensity between scrapie-
infected and healthy MSCs were determined using the unpaired non-
parametric Mann–Whitney U-test or Student’s t-test. For the different
tests, Pv0.05 was considered statistically significant.
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